| Name | Title | Contact Details |
|---|
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.
NOW AVAILABLETobramycin for Injections, USPOur ProductsCovid-19 Detection Kit and Extraction ReagentLearn MoreSpecialty Pharmaceutical Injectables & Ophthalmics Our ProductsIn The NewsFosun Partners with The National Children’s Cancer SocietyLearn More...
Everest Clinical Research ("Everest") is a full-service contract research organization (CRO) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. We serve some of the best-known companies and work with many of the most advanced drugs, biologics, and medical devices in development today.
Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.
Recursion Pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics.